Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of Other Somatic Mutations and Cytogenetic Abnormalities in Patients with NPM1 and/or FLT3-ITD Mutated AML in the Era of FLT3-Inhibitors: Real-Life Data from the Greek AML Registry

Blood (2024) 144 (Supplement 1): 5956.

https://doi.org/10.1182/blood-2024-208119

Published: 2024

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

Journal Articles

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Blood (2016) 128 (22): 5476.

https://doi.org/10.1182/blood.V128.22.5476.5476

Published: 2016

Journal Articles

Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study

Damianos Sotiropoulos, Vassilios Papadopoulos, Maria Dimou, Despoina Kyriakou, George Papaioannou, George Karavalakis, Emmanuel Papadakis, Maria Palasopoulou, Anastasia Banti, Taxiarchis Kourelis, Alexandra Kouraklis, Theodoros Marinakis, Nora-Athina Viniou, Eleftheria Hatzimichael, Diamantina Vasilatou, George Vassilopoulos, MDPhD, Panayiotis Panayiotidis, Achilles Anagnostopoulos

Blood (2015) 126 (23): 5192.

https://doi.org/10.1182/blood.V126.23.5192.5192

Published: 2015

Journal Articles

Greek Registry of Myelofibrosis: Baseline Characteristics and Therapeutic Strategy

Blood (2014) 124 (21): 5557.

https://doi.org/10.1182/blood.V124.21.5557.5557

Published: 2014

Journal Articles

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Blood (2013) 122 (21): 4084.

https://doi.org/10.1182/blood.V122.21.4084.4084

Published: 2013

Journal Articles

Distinct Cytogenetic Aberrations during the Course of Mantle Cell Lymphoma (MCL).

Stephanos I. Papadhimitriou, Ageliki Davea, Ioanna Savvidou, George Paterakis, Helen Goumakou, Elpi Griva-Kritikou, George Androutsos, Dimitris Pavlidis, Theodoros Marinakis, Nikolaos I. Anagnostopoulos, Maria Georgiakaki

Blood (2006) 108 (11): 4638.

https://doi.org/10.1182/blood.V108.11.4638.4638

Published: 2006

Journal Articles

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Athanasios G. Galanopoulos, MD, PhD, Stephanos Papadhimitriou, MD, Ioannis Tsourveloudis, MD, Evridiki Michalis, MD, Theodoros Marinakis, MD, PhD, Anastasia Tsakiridou, MD, Ioanna Savvidou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4907.

https://doi.org/10.1182/blood.V106.11.4907.4907

Published: 2005

Journal Articles

Treatment of Elderly Acute Myeloid Leukemia (AML) Patients with the Combination of Mitoxantrone and Cytarabine (MAC).

Theodoros Marinakis, MD, PhD, Athanasios G. Galanopoulos, MD, PhD, Athanasios Zomas, MD, Euridiki Michalis, MD, George Gortzolidis, MD, Anastasia Tsakiridou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, Helen Goumakou, MD, Maria Georgiakaki, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4624.

https://doi.org/10.1182/blood.V106.11.4624.4624

Published: 2005

Journal Articles

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

Theodoros Marinakis, MD, PhD, Athanasios Zomas, MD, Athanasios G. Galanopoulos, MD, PhD, Eurydiki Michalis, MD, George Gortzolidis, MD, Ioannis Tsourveloudis, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Stephanos Papadhimitriou, MD, George Paterakis, MD, Vasiliki Grigoraki, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4588.

https://doi.org/10.1182/blood.V106.11.4588.4588

Published: 2005

Journal Articles

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Vasilios Xanthopoulos, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4740.

https://doi.org/10.1182/blood.V106.11.4740.4740

Published: 2005

Journal Articles

Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Ioannis Tsourveloudis, MD, Maria Tsirogianni, MD, Stephanos Papadhimitriou, MD, Elpiniki Kritikou-Griva, MD, Nikolaos I. Anagnostopoulos, MD

Blood (2004) 104 (11): 4825.

https://doi.org/10.1182/blood.V104.11.4825.4825

Published: 2004

Journal Articles

Peripheral Blood Dendritic Cell Subsets of Patients with Type I Gaucher’s Disease Are Decreased in Number but Functionally Normal.

Argiris Symeonidis, Ilina Mitseva, Theodoros Marinakis, Constantina Repa, Alexandra Kouraklis, Nikolaos Anagnostopoulos, Nicholas Zoumbos

Blood (2004) 104 (11): 3810.

https://doi.org/10.1182/blood.V104.11.3810.3810

Published: 2004

NARROW

The Prognostic Impact of Other Somatic Mutations and Cytogenetic Abnormalities in Patients with NPM1 and/or FLT3-ITD Mutated AML in the Era of FLT3-Inhibitors: Real-Life Data from the Greek AML Registry

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study

Greek Registry of Myelofibrosis: Baseline Characteristics and Therapeutic Strategy

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Distinct Cytogenetic Aberrations during the Course of Mantle Cell Lymphoma (MCL).

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Treatment of Elderly Acute Myeloid Leukemia (AML) Patients with the Combination of Mitoxantrone and Cytarabine (MAC).

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Peripheral Blood Dendritic Cell Subsets of Patients with Type I Gaucher’s Disease Are Decreased in Number but Functionally Normal.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only